Over the course of the last few months, we have been in constant discussion with partners and key industry stakeholders to stay abreast of the challenges and complexities that each sector of the pharma industry is facing due to COVID-19.
This has included working closely with all partners and key industry stakeholders involved in CPhI Japan to determine if the show scheduled for September 2020 in Osaka would be both practical and beneficial to the market.
From a health and safety standpoint, we felt confident we could deliver a safe and secure event incorporating the highest hygiene standards.
However, CPhI Japan is an international event that attracts key industry players from around the globe. With international travel only returning gradually, Japan’s borders currently closed and each country at a different stage of recovery following the COVID-19 outbreak, it has become apparent that it would be difficult to guarantee the level of participation and high-quality experience expected of CPhI Japan.
Event Postponement
We have agreed with our partners and key industry stakeholders to postpone CPhI Japan until 14-16 April 2021 and focus on other ways in which we can support the pharma industry in the remainder of 2020, with a commitment that CPhI Japan will return stronger than ever next year.
By acting now, we hope to provide you with enough time to adjust your travel plans, avoid unnecessary expense and adapt to new opportunities the CPhI group has developed to fill the gap left by our in-person events in 2020.
Event Alternatives: Digital Networking & Learning
Whilst we will not be able to hold our in-person event in Osaka this year, we are looking into alternative digital opportunities that the CPhI Japan community can take advantage of.
We recognise that networking and knowledge sharing on a global scale is of utmost importance for Japanese manufacturers to deliver drugs to the market in a consistent way, so we endeavour to share the online opportunities that will allow this with you as soon as possible.
We sincerely apologise for any inconvenience caused and appreciate your understanding and cooperation during these unprecedented times.
CPhI Discover
KOREA PHARM & BIO 2021
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Accelerate Technological Breakthroughs in Product Innovation and Promote the Industrialization and Application of Innovative Drugs
-
The Rare Disease Market Continues to Heat Up. How Will The Global Top 10 Pharmaceutical Companies by Revenue in 2021 be Deployed?
-
Top 10 Global CDMO Rankings in 2022
-
Bayer, Merck Announced to Close Two Factories
-
5 Chinese Pharmaceutical Companies Authorized to Produce Key Ingredients of Pfizer's COVID-19 Oral Drug
-
The 88th APIChina meet you in Qingdao!
-
How Long is Amoxicillin Good for in the Fridge
-
VPi's Weakness Slows Down, And Inventory Positions Are Basically Formed
Recommend Reading
-
2020 International Pharmaceutical Raw Materials India Exhibition
-
CPhI Discover
-
CPhI & P-MEC China moves to December
-
PHARMED&HEALTHCARE VIETNAM 2019
-
Nigeria Pharma Expo 2019
-
How Much Is Osmium Price Per Ounce?
-
Johnson & Johnson acquires Momenta for $6.5 billion to develop new treatments
-
Sinopharm inactivated COVID-19 vaccines could be available by the end of 2020
-
Layout big Shandong! These two chemical groups have made great moves!
-
Holland becomes the largest importer of LNG terminal in chenille, Texas, USA